{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:18:16Z","timestamp":1767982696243,"version":"3.49.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[1999,4,1]],"date-time":"1999-04-01T00:00:00Z","timestamp":922924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[1999,4,1]],"date-time":"1999-04-01T00:00:00Z","timestamp":922924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[1999,4]]},"DOI":"10.1023\/a:1008889605137","type":"journal-article","created":{"date-parts":[[2002,12,22]],"date-time":"2002-12-22T11:51:56Z","timestamp":1040557916000},"page":"165-169","source":"Crossref","is-referenced-by-count":17,"title":["Antithrombotic and Thrombolytic Therapy for Ischemic Stroke"],"prefix":"10.1007","volume":"7","author":[{"given":"Marc","family":"Fisher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"200598_CR1","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1056\/NEJM197807132990201","volume":"299","author":"The Canadian Cooperative stroke","year":"1978","unstructured":"The Canadian Cooperative stroke. N Engl J Med 1978; 299:53\u201359.","journal-title":"N Engl J Med"},{"key":"200598_CR2","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/bmj.308.6921.81","volume":"308","author":"Antiplatelet Trialists' Collaboration","year":"1994","unstructured":"Antiplatelet Trialists' Collaboration. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994;308:81\u2013106.","journal-title":"Br Med J"},{"key":"200598_CR3","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJM199501263320408","volume":"332","author":"HJM Barnett","year":"1995","unstructured":"Barnett HJM, Eliasziw M, Meldrum HE. Drugs and surgery in the prevention of ischemic stroke. N Engl J Med 1995;332:238\u2013248.","journal-title":"N Engl J Med"},{"key":"200598_CR4","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1136\/jnnp.54.4.325","volume":"54","author":"UK-TIA Study Group.","year":"1991","unstructured":"UK-TIA Study Group. The United Kingdom transient ischemic attack (UK-TIA) aspirin trial; final results. J Neurol Neurosurg Psych 1991;54:325\u2013334.","journal-title":"J Neurol Neurosurg Psych"},{"key":"200598_CR5","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1056\/NEJM199110313251801","volume":"325","author":"The Dutch TIA Trial Study Group.","year":"1991","unstructured":"The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991;325:1261\u20131266.","journal-title":"N Engl J Med"},{"key":"200598_CR6","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/0140-6736(91)92233-R","volume":"338","author":"The SALT Collaborators Group.","year":"1991","unstructured":"The SALT Collaborators Group. Swedish low-dose trial of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 1991;338:1345\u20131349.","journal-title":"Lancet"},{"key":"200598_CR7","first-page":"1122","volume":"211","author":"The ESPS Group.","year":"1990","unstructured":"The ESPS Group. European Stroke Prevention Study. Stroke 1990;211:1122\u20131130.","journal-title":"Stroke"},{"key":"200598_CR8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-510X(96)00308-5","volume":"143","author":"HC Diener","year":"1995","unstructured":"Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1995;143:1\u201313.","journal-title":"J Neurol Sci"},{"key":"200598_CR9","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/S0140-6736(89)92327-1","volume":"1","author":"M Gent","year":"1989","unstructured":"Gent M, Blakely JA, Easton JD, et al. The Canadian-American ticlopidine study (CATS) in thromboembolic stroke. Lance 1989;1:1215\u20131220.","journal-title":"Lance"},{"key":"200598_CR10","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJM198908243210804","volume":"321","author":"WK Hass","year":"1989","unstructured":"Hass WK, Easton JD, Adams HP, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989;321:501\u2013507.","journal-title":"N Engl J Med"},{"key":"200598_CR11","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","volume":"348","author":"Caprie Steering Committee.","year":"1996","unstructured":"Caprie Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329\u20131339.","journal-title":"Lancet"},{"key":"200598_CR12","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1161\/01.STR.8.1.150","volume":"8","author":"E Genton","year":"1977","unstructured":"Genton E, Barnett HJM, Fields WJ, Lent M, Hoak JC. Cerebral ischemia: The role of thrombosis and of antithrombotic therapy. Stroke 1977;8:150\u2013175.","journal-title":"Stroke"},{"key":"200598_CR13","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1212\/WNL.39.12.1631","volume":"39","author":"EE Marsh","year":"1989","unstructured":"Marsh EE, Adams HP, Biller J, et al. Use of antithrombotic drugs in the treatment of acute ischemic stroke: A survey of neurologists in practice in the United States. Neurology 1989;39:1631\u20131634.","journal-title":"Neurology"},{"key":"200598_CR14","doi-asserted-by":"crossref","first-page":"825","DOI":"10.7326\/0003-4819-105-6-825","volume":"105","author":"RJ Duke","year":"1986","unstructured":"Duke RJ, Bloch RF, Turpie AGG, Trebilcock R, Bayer N. Intravenous heparin for the prevention of stroke progression in acute partial stable stroke. Ann Intern Med 1986;105:825\u2013828.","journal-title":"Ann Intern Med"},{"key":"200598_CR15","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(97)04011-7","volume":"349","author":"International Stroke Trial Collaborative Group.","year":"1997","unstructured":"International Stroke Trial Collaborative Group. The International Stroke Trial (IST): A randomized trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischaemic stroke. Lancet 1997;349: 1569\u20131581.","journal-title":"Lancet"},{"key":"200598_CR16","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1056\/NEJM199512143332402","volume":"333","author":"R Kay","year":"1995","unstructured":"Kay R, Wong KS, Ling Y, et al. Low-molecular-weight heparin for the treatment of acute ischemic stroke. N Engl J Med 1995;333:1588\u20131593.","journal-title":"N Engl J Med"},{"key":"200598_CR17","unstructured":"Trial of Org10172 in acute stroke treatment. Presented at the 6th European Stroke Conference, Amsterdam, May 1997."},{"key":"200598_CR18","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S0140-6736(97)04010-5","volume":"349","author":"CAST","year":"1997","unstructured":"CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomized placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet 1997;349:1641\u20131649.","journal-title":"Lancet"},{"key":"200598_CR19","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1056\/NEJM199512143332401","volume":"333","author":"The National Institute of Neurological DisordersStroke rt-PA Stroke Study Group.","year":"1995","unstructured":"The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581\u20131587.","journal-title":"N Engl J Med"},{"key":"200598_CR20","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1001\/jama.1995.03530130023023","volume":"274","author":"W Hacke","year":"1995","unstructured":"Hacke W, Kaste M, Fieschi, C, et al. for The ECASS Study Group. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. JAMA 1995;274:1017\u20131025.","journal-title":"JAMA"},{"key":"200598_CR21","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jama.1996.03540120039031","volume":"276","author":"GA Donnan","year":"1996","unstructured":"Donnan GA, Davis SM, Chambers BR, et al. for the Australian Streptokinase (ASK) Trial Study Group. Streptokinase for acute ischemic stroke with relationship to time of administration. JAMA 1996;276:961\u2013966.","journal-title":"JAMA"},{"key":"200598_CR22","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM199607183350301","volume":"335","author":"Multicenter Acute Stroke Trial-Europe Study Group.","year":"1996","unstructured":"Multicenter Acute Stroke Trial-Europe Study Group. Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med 1996;335:145\u2013150.","journal-title":"N Engl J Med"},{"key":"200598_CR23","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/S0140-6736(95)92049-8","volume":"346","author":"Multicenter Acute Stroke Trial-Italy","year":"1995","unstructured":"Multicenter Acute Stroke Trial-Italy (MAST-I) Group. Randomized controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet 1995;346:1509\u20131514.","journal-title":"Lancet"},{"key":"200598_CR24","first-page":"164","volume":"27","author":"GJ Del Zoppo","year":"1996","unstructured":"Del Zoppo GJ, Higashida RT, Furlan AJ, et al. The Prolyse in Acute Cerebral Thromboembolism Trial (PROACT); results of 6 mg dose tier. Stroke 1996;27:164.","journal-title":"Stroke"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1008889605137.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1023\/A:1008889605137\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1008889605137.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T07:21:45Z","timestamp":1754637705000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1023\/A:1008889605137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,4]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1999,4]]}},"alternative-id":["200598"],"URL":"https:\/\/doi.org\/10.1023\/a:1008889605137","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"value":"0929-5305","type":"print"},{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,4]]}}}